Linked Life Data

18723492

Source:http://linkedlifedata.com/resource/pubmed/id/18723492

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18723492rdf:typepubmed:Citationlld:pubmed
pubmed-article:18723492lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:18723492lifeskim:mentionsumls-concept:C0346647lld:lifeskim
pubmed-article:18723492lifeskim:mentionsumls-concept:C0677850lld:lifeskim
pubmed-article:18723492lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:18723492pubmed:issue8lld:pubmed
pubmed-article:18723492pubmed:dateCreated2008-8-25lld:pubmed
pubmed-article:18723492pubmed:abstractTextPancreatic adenocarcinoma confers one of the highest mortality rates in malignant human tumors with very poor prognosis. Because as yet no treatments are available that produce a substantial survival benefit for this fatal neoplasia, new therapeutic concepts are urgently required to support cancer standard treatment. In search of tumor-associated gangliosides with therapeutic background, we probed a random collection of cancerous and adjacent normal postoperative tissue samples from 38 patients for the expression of CD75s- and iso-CD75s-gangliosides. We exhaustively analyzed the expression of CD75s-1-ganglioside (IV(6)Neu5Ac-nLc4Cer) and structurally closely related iso-CD75s-1-ganglioside (IV(3)Neu5Ac-nLc4Cer) by means of immunohistology of cryosections and semiquantitative TLC of tissue lipid extracts combined with mass spectrometry. CD75s-1- and iso-CD75s-1-ganglioside showed an elevated expression in 42% and 66% of the tumors, respectively, indicating a significant association with neoplastic transformation (P = 0.001). Thus, increased expression of CD75s-1- and iso-CD75s-1-gangliosides renders these cell surface molecules promising candidates for oncologic applications. Further statistical analysis revealed a significant enhancement of CD75s-1-ganglioside in the group of less differentiated tumors (grade >2) suggesting this ganglioside as a potential marker for poor differentiation. The CD75s-specific antitumor drug rViscumin, which represents the recombinant counterpart of the ribosome-inactivating lectin viscumin, has successfully passed clinical phase I trials and provides an opportunity for treating pancreatic cancer. Consequently, if an enhanced expression is existent in malignant tissues, we propose the targeting of CD75s-gangliosides with rViscumin as a novel potential strategy in adjuvant treatment of pancreatic malignancies.lld:pubmed
pubmed-article:18723492pubmed:languageenglld:pubmed
pubmed-article:18723492pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:citationSubsetIMlld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18723492pubmed:statusMEDLINElld:pubmed
pubmed-article:18723492pubmed:monthAuglld:pubmed
pubmed-article:18723492pubmed:issn1535-7163lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:SenningerNorb...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:SchmidtM...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:HaierJörgJlld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:DenzAxelAlld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:BerkenkampSte...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:DreisewerdKla...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:PilarskyChris...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:Peter-Katalin...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:MüthingJohann...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:GrützmannRobe...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:DistlerUteUlld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:SouadyJamalJlld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:Drmi?-HofmanI...lld:pubmed
pubmed-article:18723492pubmed:authorpubmed-author:HülsewigMarce...lld:pubmed
pubmed-article:18723492pubmed:issnTypePrintlld:pubmed
pubmed-article:18723492pubmed:volume7lld:pubmed
pubmed-article:18723492pubmed:ownerNLMlld:pubmed
pubmed-article:18723492pubmed:authorsCompleteYlld:pubmed
pubmed-article:18723492pubmed:pagination2464-75lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:meshHeadingpubmed-meshheading:18723492...lld:pubmed
pubmed-article:18723492pubmed:year2008lld:pubmed
pubmed-article:18723492pubmed:articleTitleTumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer.lld:pubmed
pubmed-article:18723492pubmed:affiliationInstitute for Medical Physics and Biophysics, University of Münster, Robert-Koch-Strasse 31, Münster, Germany.lld:pubmed
pubmed-article:18723492pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18723492pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18723492lld:pubmed